New study to prevent metastasis of breast cancer
Multiple media channels, both national and international, have echoed a study published by Robert E. Coleman (University of Sheffield) in the Lancet Oncology and which involved Roger Gomis (IRB Barcelona). The work allows early detection of patients who could benefit from zoledronic acid and those who should avoid it. Such early detection would thus accelerate the administration of the first preventive treatment for metastasis.
Link to JANO
Link to La Vanguardia
Link to EFE Futuro
Link to BioTech
Link to Medindia
Link to Medical Xpress
Link to ecancer
Related content
News
The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.
Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.
Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.
To mark World Cancer Day, the programme El Matí de Barcelona Betevé broadcasted by Radio Barcelona has interviewed Roger Gomis, ICREA Researcher and head of the Growth Control and Metastasis Lab at IRB Barcelona. During the interview, he talked about metastasis, the process by which a tumour spreads to the rest of the body, allowing cancer cells to adapt to new environments “What we are focusing on in our lab is precisely how this cell adaptation and plasticity comes about,” says Gomis.
